Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

NCTNCT02577848 (opens ClinicalTrials.gov in a new tab)Other idGLP-1-301xnk
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
90 participants (estimated)
Sponsor
Chinese PLA General Hospital · Other
Design
Randomized · Double masking
Countries
1 country

China

Start
Oct 2015
Primary completion
Oct 2016 (estimated)
Completion
Oct 2016 (estimated)
First posted
16 Oct 2015 (estimated)
Last update posted
19 Oct 2015 (estimated)
Conditions
Myocardial Infarction

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. N/A

    GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

    NCT02577848

    Oct 2015 to est. Oct 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

Interventions

  • GLP-1Drug
  • PlaceboDrug

Arms2

  • Experimental

    GLP-1 group

    liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.

  • Placebo comparator

    placebo

    placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. left ventricular ejection fractions

    Time frame · at 3 months

    Registry description

    The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by transthoracic echocardiography at 3 months .

Secondary outcomes(2)

  1. 6-minute walk distance

    Time frame · at 3 months

    Registry description

    The change in6-minute walk distance at 3 months after treatment.

  2. treatment-emergent adverse events

    Time frame · at 3 months

    Registry description

    Treatment-emergent adverse events (TEAEs): hypoglycaemia, pancreatitis, thyroid cancer

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2012

8 results

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

Lønborg et al. 2012European heart journalcited by 421

PMID 21920963DOI 10.1093/eurheartj/ehr309PUB-21920963

Rights unknown8 results
Source linkSee results (8)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: non-ST-segment elevation myocardial infarction (NSTEMI ) Exclusion Criteria: 1. unconscious at presentation 2. had ST-segment elevation acute myocardial infarction 3. NSTEMI requiring emergency percutaneous coronary angiography 4. valvular heart disease 5. cardiogenic shock 6. hypoglycaemia 7. diabetic ketoacidosis 8. had a history of myocardial infarction 9. stent implantation 10. renal insufficiency 11. had previously undergone coronary artery bypass surgery.

PepBank is a research reference. Talk to a doctor before you use any peptide.